Healthcare
Immunovant, Inc.(IMVT)
Live Price
Offline$34.93
+3.93% today
1Y Change
+113.40%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $5.52B
- Revenue Growth
- 0.0%
- EPS Growth
- -45.2%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Immunovant, Inc. (IMVT) is a Healthcare stock with a market cap of $5.52B and listed on NASDAQ. The stock last traded around $34.93 and up 113.4% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -45.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -45.2%, free cash flow -75.5% with operating margin 0.0% and ROIC -49.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines IMVT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 4, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -45.2%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.1% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 4, 2026 | โ | -4.8% | +0.6% | โ |
2026 Feb 6, 2026 | +15.3% | +1.6% | -4.8% | -2.4% |
2025 Nov 10, 2025 | -1.4% | -2.1% | +4.0% | -2.6% |
Benchmark Edge
IMVT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IMVT
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IMVT Max Drawdown
-20.98%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IMVT and SPY.
Company Overview
Immunovant, Inc.
NASDAQ Global Select
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
- Leadership
- Eric Venker
- IPO Date
- Jun 21, 2019
- Employees
- 362
- Street Address
- 320 West 37th Street
- Mailing
- New York City, NY, 10018
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 917 580 3099
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 5.0
Growth
- Revenue
- 0.0%
- EPS
- -45.2%
- Free Cash Flow
- -75.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -65.8%
- ROIC
- -49.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 15.74
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.